Selective serotonin reuptake inhibitor-induced akathisia

Journal of the American Pharmacists Association

Volumn 49, Issue 2, 2009, Pages

  Koliscak, Lindsey P ^a   Makela, Eugene H ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Adverse drug effects; Akathisia; Pharmacotherapy; Serotonin receptor modulators

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

AKATHISIA; ANIMAL; HUMAN; REVIEW; RISK FACTOR;

AKATHISIA, DRUG-INDUCED; ANIMALS; HUMANS; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 67449099381     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2009.08083     Document Type: Article

References (46)

1. Akagi H, Kumar TM. Lesson of the week: akathisia: overlooked at a cost. BMJ. 2002;324:1506-7.
2. American Psychiatric Association. Other conditions that may be a focus of clinical attention. In: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision. Washington, DC: American Psychiatric Association; 2000:735, 800-2.
3. Lipinski, JF, Mallya G, Zimmerman P, Pope HG. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry. 1989;50:339-42.
4. Bauer M, Hellweg R, Baumgartner A. Fluoxetine-induced akathisia does not reappear after switch to paroxetine. J Clin Psychiatry. 1996;57:593-4.
5. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol. 1998;12:194-214.
6. Walker L. Sertraline-induced akathisia and dystonia misinterpreted as a panic attack. Psychiatr Serv. 2002;53:1477-8.
7. Altshuler LL, Pierre JM, Wirshing WC, Ames D. Sertraline and akathisia. J Clin Psychopharmacol. 1994;14(4):278-9.
8. Involuntary movement disorders. In: Kaufman DM, Ed. Clinical neurology for psychiatrists. Philadephia: W.B. Saunders; 2001:482-7.
9. Barnes TRE. Barnes Akathisia Rating Scale (BARS). In: Rush AJ, First MB, Blacker D, Eds. Handbook of psychiatric measures. 2nd ed. Arlington, VA: American Psychiatric Publishing, Inc; 2008:156-57.
10. Olivera AA. Sertraline and akathisia: spontaneous resolution. Biol Psychiatry. 1997;41:241-2.
11. Hensley PL, Reeve A. A case of antidepressant-induced akathisia in a patient with traumatic brain injury. J Head Trauma Rehabil. 2001;16:302-5.
12. Baldassano CF, Truman CJ, Nierenberg A, et al. Akathisia: a review and case report following paroxetine treatment. Compr Psychiatry. 1996;37:122-4.
13. Breggin PR. Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): a review and analysis. Int J Risk Saf Med. 2003;16:31-49.
14. Kurzthaler I, Hotter A, Miller C, et al. Risk profile of SSRIs in elderly depressive patients with co-morbid physical illness. Pharmacopsychiatry. 2001;34:114-8.
15. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996;57:449-54.
16. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf. 1999;20:277-87.
17. Schillevoort I, Puijenbroek EP, Boer A, et al. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol. 2002;17:75-9.
18. Hamilton MS, Opler LA. Akathisia, suicidality, and fluoxetine. J Clin Psychiatry. 1992;53:401-6.
19. Hansen L, Wilkinson DG. Drug induced akathisia, suicidal ideation and its treatment in the elderly. Int J Geriatr Psychiatry. 2001;16:231-2.
20. Hansen L. Fluoxetine dose-increment related akathisia in depression: implications for clinical care, recognition and management of selective serotonin reuptake inhibitor-induced akathisia. J Psychopharmacol. 2003;17:451-2.
21. Settle EC. Akathisia and sertraline. J Clin Psychiatry. 1993;54:321.
22. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-6.
23. Eberstein S, Adler LA, Angrist B. Nefazodone and akathisia. Biol Psychiatry. 1996;40:798-9.
24. Gold Standard, Inc. Fluoxetine: clinical pharmacology. Accessed at www.clinicalpharmacology.com, February 1, 2009.
25. Gold Standard, Inc. Paroxetine: clinical pharmacology. Accessed at www.clinicalpharmacology.com, February 1, 2009.
26. Gold Standard, Inc. Risperidone: clinical pharmacology. Accessed at www.clinicalpharmacology.com, February 1, 2009.
27. Gold Standard, Inc. Haloperidol: clinical pharmacology. Accessed at www.clinicalpharmacology.com, February 1, 2009.
28. Markkula J, Helenius H, Lauerma H. On the relationship of atypical and low-dose conventional antipsychotics with akathisia in a clinical patient population. Nord J Psychiatry. 2007;61:152-7.
29. Chong SA, Tan CH. Fluvoxamine and akathisia. J Clin Psychopharmacol. 1996;16:334-5.
30. Shihabuddin L, Rapport D. Sertraline and extrapyramidal side effects. Am J Psychiatry. 1994:151:288.
31. Poyurovsky M, Meerovich I, Weizman A. Beneficial effect of lowdose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient. Int Clin Psychopharmacol. 1995;10:111-4.
32. Opler LA. Sertraline and akathisia. Am J Psychiatry. 1994:151:620-1.
33. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998;32:692-7.
34. Gold Standard, Inc. Escitalopram: clinical pharmacology. Accessed at www.clinicalpharmacology.com, February 1, 2009.
35. Seedat S, Lockhat R, Kaminer D, et al. An open trial of citalopram in adolescents with post-traumatic stress disorder. Int Clin Psychopharmacol. 2001;16:21-5.
36. Adler LA, Angrist BM. Paroxetine and akathisia. Biol Psychiatry. 1995;37:336-7.
37. Arya DK. Existing brain condition may predispose to SSRI-induced extrapyramidal symptoms. Aust N Z J Psychiatry. 1997;31:773-4.
38. Caley CF. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother. 1997;31:1481-9.
39. Muly EC, McDonald W, Steffens D, Book S. Setotonin syndrome produced by a combination of fluoxetine and lithium. Am J Psychiatry. 1993;150:1565.
40. Schaller JL, Rawlings DB. Escitalopram in adolescent major depression. MedGenMed. 2005;7:6.
41. Chelben J, Strous RD, Lustig M, Baruch Y. Remission of SSRI-induced akathisia after switch to nefazodone. J Clin Psychiatry. 2001;62:570-1.
42. Reimherr FW, Chouinard G, Cohn CK, et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry. 1990;51(suppl B):18-27.
43. Pohl R, Yeragani VK, Balon R, Lycaki H. The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry. 1988;49:100-4.
44. Back I, Taubert M. Akathisia and an unusual symptomatic treatment: a case report. Palliat Med. 2007;21:713-5.
45. Hoaken PCS. An alert to extrapyramidal side-effects from SSRIs. Can J Psychiatry. 1995;40:51.
46. Klee B, Kronig MH. Case report of probably sertraline-induced akathisia. Am J Psychiatry. 1993;150:986-97.